DRMTY News and Press, Dr. Martens

2024-07-01 10:59:21 ET Summary Dr. Martens plc reported expectedly weak H2/FY2024 results with a decline in earnings and sales, especially in the US market's wholesale revenues. DOCMF plans to implement a cost savings plan to decrease costs by £20-25 million to improve profit...

2024-06-21 11:18:37 ET Summary Abercrombie & Fitch has driven an impressive brand turnaround, fueled by changing fashion trends making Abercrombie brands more attractive to young people. Investors should still note the risk of ever-changing fashion trends that could deteriorat...

2024-05-30 13:04:04 ET Dr. Martens plc. (DOCMF) H2 2024 Earnings Conference Call May 30, 2024 4:30 am ET Corporate Participants Kenneth Wilson - Chief Executive Officer Giles Wilson - Chief Financial Officer Conference Call Participants John Stevenson - P...

2024-04-17 04:20:49 ET Summary Dr. Martens' FY2025 outlook shows weakness in the wholesale segment for the upcoming fiscal year after the segment's already very bad FY2024 performance. The company's margins are suppressing in the upcoming fiscal year with the lower expected revenu...

2024-03-11 17:40:07 ET Summary Dr. Martens aims to become a £2 billion revenue company by focusing on direct-to-consumer sales, global expansion, and increasing online sales. The company has a strong brand with steady brand awareness and a loyal customer base. Despite a r...

2024-01-10 11:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International growth e...

2024-01-03 15:41:33 ET More on Dr. Martens plc Dr. Martens: Don't Miss This Opportunity Dr. Martens plc. (DOCMF) H1 2024 Earnings Call Transcript Historical earnings data for Dr. Martens plc Dividend scorecard for Dr. Martens plc Financial information...

2023-12-01 00:01:00 ET Summary Dr. Martens stock has plummeted over 80% since its IPO in early 2021, but the company's earnings and financials remain strong. H1 FY2024 disappointed, but long-term growth remains. The company is undervalued and has a fair value of £0.96 per...

2023-11-30 15:38:03 ET Dr. Martens plc. (DOCMF) H1 2024 Earnings Conference Call November 30, 2023, 03:30 AM ET Company Participants Bethany Barnes - Head of Investor Relations Kenneth Wilson - Chief Executive Officer Paul Mason - Chair, Dr Martens Jon Mortim...

2023-06-15 00:04:22 ET Summary Dr. Martens has a loyal fanbase that continues to grow. Its high-quality production and timeless design are key value drivers. The company has achieved a CAGR of 43% in revenue and maintains a strong EBITDA margin of 20%. Dr. Martens is trading a...